Announcement • Apr 24
PMV Pharmaceuticals, Inc. Announces Board Changes, Effective June 4, 2026 PMV Pharmaceuticals, Inc. announced a leadership transition on its Board of Directors. Laurie Stelzer, who has served as a member of the Board since 2020, has been appointed Chair of the Board, succeeding Rich Heyman, Ph.D., effective at the Company’s 2026 Annual Meeting of Stockholders on June 4, 2026. Dr. Heyman’s term as a member and Chair of the Board will expire at the Meeting, and Dr. Heyman will not stand for reelection. Ms. Stelzer brings more than 25 years of senior finance and business development leadership experience across the biopharmaceutical industry, with a proven track record of guiding companies through key strategic and value-creating milestones. Ms. Stelzer is a seasoned Chief Financial Officer (CFO) and public company Board Director, most recently serving as CFO at Kailera Therapeutics a clinical-stage biopharmaceutical company focused on the treatment of obesity and related conditions. She currently serves on the Boards of Sionna Therapeutics, Spyre Therapeutics, Inc, and MBX Biosciences, Inc. Ms. Stelzer has held leadership roles in finance, treasury, global accounting, business development, project management, and site operations for a range of biopharmaceutical companies including as CFO of Orna Therapeutics, Mirati Therapeutics, Inc., Arena Pharmaceuticals, Inc., and Halozyme Therapeutics, Inc. Earlier in her career, she held senior management roles at Shire Plc and Amgen, Inc., and previously served on the Board of Surface Oncology, Inc. and Longboard Pharmaceuticals. She earned an M.B.A. from University of California, Los Angeles, Anderson School of Management and a B.S. in accounting from Arizona State University. Announcement • Apr 23
PMV Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2026 PMV Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2026. New Risk • Feb 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$94m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$72.9m market cap). 
